Cell and gene ther­a­pies from acad­e­mia: EMA to help 5 projects go­ing af­ter un­met clin­i­cal needs

The Eu­ro­pean Med­i­cines Agency said Thurs­day that it’s launch­ing a new pi­lot pro­gram to help aca­d­e­m­ic and oth­er non­prof­it re­searchers de­vel­op­ing ad­vanced ther­a­py med­i­c­i­nal prod­ucts, which in­cludes cell and gene ther­a­pies.

Aca­d­e­mics have proven to be enor­mous­ly use­ful in feed­ing new prod­ucts, like chimeric anti­gen re­cep­tor (CAR)-T cell ther­a­pies, some of which were first de­vel­oped by Memo­r­i­al Sloan Ket­ter­ing Can­cer Cen­ter and the Uni­ver­si­ty of Penn­syl­va­nia, and ush­ered to the mar­ket by bio­phar­ma com­pa­nies. Jean Ben­nett, for­mer­ly with the Uni­ver­si­ty of Penn­syl­va­nia, al­so saw her re­search lead to the ap­proval of gene ther­a­py Lux­tur­na, which Roche now owns.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER